@article { author = {Mirmalek, Seyed Abbas and Kani, Fatemeh Elham and Mehrabi, Arianeb and Chavoshi-Nejad, Mehdi and Salimi-Tabatabaee, Seyed Alireza and Parsa, Yekta and Yadollah-Damavandi, Soheila and Parsa, Tina and Aidun, Amin}, title = {Breast Carcinoma; Human Epidermal Growth Factor Receptor-2 (HER-2) and Grading Correlation}, journal = {International Journal of Travel Medicine and Global Health}, volume = {3}, number = {3}, pages = {95-97}, year = {2015}, publisher = {International Travel Medicine Center of Iran}, issn = {2322-1100}, eissn = {2476-5759}, doi = {10.20286/ijtmgh-030395}, abstract = {Introduction: Overexpression of Human Epidermal Growth factor Receptor-2 (HER-2) is one of the most important prognostic and predictive factors of breast cancer, observed in 25% - 30% of breast carcinoma patients leading to poor prognosis and feasible anti HER-2 antibody drugs. The objective of this study was to evaluate the HER-2 frequency in target population and its correlation with histologic grade as well as tumor pathology, estrogen receptor (ER) and P53 in our patients. Methods: A total of 300 cases (all female) aged 24- 80 year, were randomly selected from patients who were admitted in two of the Tehran University of Medical Sciences affiliated centers (Emam Khomeini Cancer Institute and Shariati hospital) over a 2-year period (2013-2014). Assessment of tumors for HER-2, P53, ER, pathological type and histologic grade was performed. HER-2 over expression defined as three plus (+++) in immunohistochemistry (IHC). Results: The mean age was 49.6±11 years. HER-2 over expression was seen in 34% of the patients. Significant correlations were found between HER-2+, P53+ and high histologic grade and ER (P<0.05). However, there was no significant correlation between HER-2 and pathologic type of tumors in our study. Conclusion: Co-expression of several poor prognostic biomarkers in breast cancer (HER-2 +, P53 +, ER- , high grade) may predict more aggressive phenotype, worse disease and lower overall survival in these patients.}, keywords = {Breast carcinoma,Tumor Grading,Human Epidermal Growth Factor Receptor-2 (HER-2)}, url = {https://www.ijtmgh.com/article_33212.html}, eprint = {https://www.ijtmgh.com/article_33212_52ae3909e547e4b7781940b522fad7b0.pdf} }